Apeiron Biologics, Paladin sales and marketing update

Apeiron granted Paladin exclusive rights to commercialize APN311, a chimeric mAb against GD2, in Canada and sub-Saharan Africa. The compound is in Phase III testing in Europe for high-risk neuroblast...